logo-loader
RNS
viewReNeuron Group PLC

Block Listing Review and TVR

/**/ sup{font-size:80%}h1{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h2{margin:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h4{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h5{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h6{margin:0cm;margin-bottom:.0001pt;text-align:right;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .ba{size:595.3pt 841.9pt;margin:72.0pt 106.25pt 49.65pt 90.0pt;}div.ba{}h1.ch{text-indent:117.0pt}span.ci{font-weight:normal}table.ck{margin-left:-5.4pt;border-collapse:collapse}td.cf{width:176.65pt;padding:0cm 5.4pt 0cm 5.4pt}span.cg{font-size:11.0pt;font-family:"Calibri","sans-serif"}td.cc{width:211.6pt;padding:0cm 5.4pt 0cm 5.4pt}h3.cd{text-align: right}span.ce{font-size:11.0pt; font-family:"Calibri","sans-serif"} p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;}h1.ca{text-align: center}p.cl{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align: center}p.cm{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: center}p.cn{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align:justify}span.bx{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}table.co{margin-left:-5.4pt;border-collapse:collapse;border:none}td.bv{width:189.2pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bu{width:187.75pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.bt{width:189.2pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt} td.bs{width:187.75pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.cp{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: justify}span.bq{font-size: 9.0pt;font-family:"Calibri","sans-serif"}p.cq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;margin-right:1.45pt;text-align:justify}span.cr{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.bn{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}table.cs{width:411.1pt}tr.bh{height:17.0pt}td.bk{padding:0cm 0cm 0cm 0cm;height:17.0pt}p.ct{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold} span.bm{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}td.bi{width:25.5%;padding:0cm 0cm 0cm 0cm; height:17.0pt}span.bj{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.cu{font-family:"Calibri","sans-serif";color:black;font-size:11.0pt}p.bd{margin-top:0cm;margin-right:0cm;margin-bottom:15.0pt;margin-left: 0cm;text-align:justify;background:white}span.be{font-family:"Calibri","sans-serif"}p.cv{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; margin-bottom: 0cm; margin-left: -35.45pt; margin-right: -38.3pt; margin-top: 0cm; text-indent: 35.45pt}span.bc{font-family:"Arial","sans-serif";color:red} /**/
RNS Number : 7890K
ReNeuron Group plc
02 September 2019
 

 

2 September 2019

AIM: RENE

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Block Listing Review and Total Voting Rights

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.

 

Name:

ReNeuron Group plc

Name of Scheme:

ReNeuron Share Option Schemes

Period of Return:

From 1 March 2019  to 31 August 2019

Balance of unallotted securities under scheme(s) from previous return:

902,825 Ordinary Shares (of 1p each)

 

Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for):

N/A

Less: Number of securities issued/allotted under scheme(s) during period

 

186,084

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

716,741 Ordinary Shares

Number and class of securities originally admitted and the date of admission:

20,000 ordinary shares on 13 May 2010

 

 

Total Voting Rights

At 31 August 2019, the Company had 31,832,270 ordinary shares in issue, each carrying one voting right. As the Company holds no ordinary shares in treasury, the figure of 31,832,270 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 

ENDS

 

ENQUIRIES:

 

 

ReNeuron

+44 (0)20 3819 8400

Olav Hellebø, Chief Executive Officer


Michael Hunt, Chief Financial Officer

 

 


Buchanan

+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham

 

 


Stifel Nicolaus Europe Limited

+44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace, Ben Maddison

(NOMAD and Joint Broker)

 

 


N+1 Singer

+44 (0) 20 7496 3000

Aubrey Powell, James Moat, Mia Gardner

(Joint Broker)


 

 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCBLGDIBXXBGCG

Quick facts: ReNeuron Group PLC

Price: 147.5

Market: LSE
Market Cap: £46.95 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18